Treatment of Intertriginous and Genito-Anal Psoriasis;Therapie der Intertriginösen und Genitoanalen Psoriasis

Aktuelle Dermatologie

Volumn 29, Issue 12, 2003, Pages 505-508

  Thaci D ^a   Patzold S ^a   Kaufmann, R ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIPSORIASIS AGENT; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN A; ETRETIN; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PIMECROLIMUS; PREDNICARBATE; TACALCITOL; TACROLIMUS; TAZAROTENE;

ARTICLE; ATOPIC DERMATITIS; CANDIDIASIS; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; HUMAN; INTERTRIGO; PATHOGENESIS; PSORIASIS; PUVA; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 1342268721     PISSN: 03402541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814297     Document Type: Article

References (20)

1. Farber EM, Nall L. Genital psoriasis. Cutis 1992; 50: 263-266
2. Van de Kerkhof P. Clinical features. In: Van de Kerkhof P (ed). Textbook of Psoriasis. Oxford: Blackwell, 1999
3. Schöfer H. Psoriasis intertriginosa. In: Boehncke WH, Kaufmann R (eds). Moderne Antipsoriatika-Wirkmechanismen und klinische Anwendung. Bremen, London, Boston: Unimed, 2001
4. Buechner SA. Common skin disorders of the penis. BJU Int 2002; 90: 498-506
5. Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Pediatr 1988; 113: 1037-1039
6. Herbst RA, Hoch O, Kapp A, Weiss J. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol 2000; 42: 885-887
7. Seebacher C. Candida in dermatology. Mycoses 1999; 42 Suppl 1: 63-67
8. Flytstrom I, Bergbrant IM, Brared J, Brandberg LL. Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol 2003; 83: 121-123
9. Lebwohl M, Peets E, Chen V. Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. Int J Dermatol 1993; 32: 830-831
10. Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001; 44: 77-82
11. Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996; 135: 647-650
12. Travis LB, Silverberg NB. Psoriasis in infancy: therapy with calcipotriene ointment. Cutis 2001; 68: 341-344
13. Gollnick HP, Finzi AF, Marks R et al. Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM). Dermatology 1999; 199: 40-46
14. Wollina U. Genital ulcers in a psoriasis patient using topical tazarotene. Br J Dermatol 1998; 138: 713-714
15. Jemec GB, Baadsgaard O. Effect of cyclosporine on genital psoriasis and lichen planus. J Am Acad Dermatol 1993; 29: 1048-1049
16. Freeman AK, Linowski GJ, Brady C et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564-568
17. Shelley ED, Shelley WB. Inframammary, intertriginous, and decubital erosions due to etretinate. Cutis 1990; 45: 111-113
18. Ramsay B, Bloxham C, Eldred A et al. Blistering, erosions and scarring in a patient on etretinate. Br J Dermatol 1989; 121: 397-400
19. Stern RS, Bagheri S, Nichols K. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47: 33-39
20. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-1537